Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

CNS 1

Conditions

Melanoma 98Carcinoma, Non-Small-Cell Lung 32Neoplasms 22Neoplasm Metastasis 14Carcinoma, Renal Cell 13Prostatic Neoplasms 12Lung Neoplasms 12Small Cell Lung Carcinoma 10Diabetes Mellitus, Insulin-Dependent, 12 10Pancreatic Neoplasms 7Uveal Melanoma 6Skin Neoplasms 6Ovarian Neoplasms 6Brain Neoplasms 6Advanced Cancer 6Squamous Cell Carcinoma of Head and Neck 5Sarcoma 5Mesothelioma 5Multiple Myeloma 4Lymphoma, Non-Hodgkin 4Lymphoma 4Kidney Neoplasms 4Hodgkin Disease 4Head and Neck Neoplasms 4Carcinoma, Transitional Cell 4Carcinoma, Merkel Cell 4Carcinoma, Hepatocellular 4Carcinoma 4Breast Neoplasms 4Various Advanced Cancer 3

Interventions

trastuzumab deruxtecan 1omburtamab I-131 1merphos 1epothilone B 1adavosertib 1XL647 1Transplantation, Autologous 1Sorafenib 1Rituximab 1Radiotherapy 1Radiation 1Nivolumab 1Methotrexate 1Ipilimumab 1Bevacizumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Has results × Meningeal Carcinomatosis × Ipilimumab × Clear all
NCT02939300 2025-11-14

Ipilimumab and Nivolumab in Leptomeningeal Metastases

Massachusetts General Hospital

Phase 2 Completed
18 enrolled 17 charts
CNS

Meningeal Carcinomatosis

Data powered by HemOnc (CC BY 4.0) Colophon âš¡